Business Model
B2B
Pharmaceutical Industry
Out Licencing + R&D
Assets:
• Expandable IP portfolio + expertise
• Production capacity ( prototypes TRL 1-5, ≈ kg)
• CRO/CDMO & Academic partners
Feasibility Validation
TRL 1 – 4 (3 à 6 months)
Co-Development
TRL 5 GLP (12 à 24 months)
Out Licencing
TRL 6 – 8 GLP / GMP
39%
CORE PATENT
APPLICATION SPECIFIC PATENTS